Stay up to date on the latest oncology and nursing conferences.
Meredith Cummings on Using Machine Learning to Predict Treatment-Related Adverse Events
Meredith Cummings BSN, RN, OCN, highlights her research on machine learning and its potential application in optimizing symptom management.
Cancer Vaccine mRNA-4157 Improves Recurrence-Free Survival for Patients With High-Risk Melanoma
Adjuvant mRNA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.
Multidisciplinary Teamwork Yields Improvements in HSCT Workflow and Care
Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP; and Tia Wheatley, DNP, RN, AOCNS, BMTCN, highlight the value of multidisciplinary approaches in hematopoietic stem cell transplantation care.
Cabozantinib Plus Nivolumab/Ipilimumab Minimizes Disease Progression in Metastatic Soft Tissue Sarcoma
Phase 2 findings show that adding a tyrosine kinase inhibitor to dual immunotherapy curbed disease progression in patients with metastatic soft tissue sarcoma.
Pembrolizumab, In Addition To Chemotherapy, Misses Mark in TKI-Resistant, EGFR+ NSCLC
Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.
Repeated Hematologic Evaluations May Not be Necessary for Patients Receiving ICIs
Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.
Sintilimab Minimizes Disease Recurrence Rates in Locally Advanced Nasopharyngeal Carcinoma
Sintilimab plus chemoradiotherapy was associated with better event-free survival rates in locally advanced nasopharyngeal carcinoma than chemoradiotherapy alone.
Frontline Pembrolizumab Plus Axitinib Continues To Show Benefits in Advanced ccRCC at 5-Year Follow-Up
A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.
Second-Line Axi-Cel Bests HDT/HSCT in Prolonging Overall Survival in R/R LBCL
Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.
Erdafitinib Reduces Risk of Death by 36% in FGFR-Altered Urothelial Cancer
Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.
Trastuzumab Deruxtecan Demonstrates Clinical Activity Across Numerous HER2+ Solid Tumors
In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.
Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors
Nirogacestat significantly reduced pain scores for patients with desmoid tumors.
Vorasidenib Demonstrates PFS Benefit in IDH-Mutant Low-Grade Glioma
Vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma.
Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer
An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.
Mirvetuximab Soravtansine Elicits Practice-Changing Outcomes in Frα+ Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator's choice chemotherapy.
Nivolumab Plus AVD Confers PFS Benefit for Treatment of Advanced-Stage Hodgkin Lymphoma
Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.
FOLFOX Demonstrates Comparable Efficacy to Chemoradiation for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.
Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS
Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.
Adding Ribociclib to Endocrine Therapy Yields 25% Relative Reduction in Risk of Invasive Disease In Patients With HR+/HER2– Early Breast Cancer
Statistically and clinically meaningful improvements in invasive disease-free survival were observed among patients with hormone receptor–positive/HER2-negative early breast cancer who received ribociclib in addition to endocrine therapy.
Simple Hysterectomy May Replace Radical Hysterectomy as Standard of Care in Low-Risk, Early-Stage Cervical Cancer
The 3 year-pelvic recurrence rates with simple hysterectomy were comparable with those of radical hysterectomy among patients with low-risk, early-stage cervical cancer.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Alyssa Ridad BSN-RN, OCN; and Amanda McKaig, BSN, RN, OCN, discuss oncology nurse perceptions of medical cannabis.
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.
Improved Survival Outcomes Are Observed In GI Cancers With Medicaid Expansion
Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.
Minimally Invasive Distal Pancreatectomy Proves Noninferior to Open Distal Pancreatectomy in Resectable Pancreatic Cancer
Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.
Johanna Garibaldi On Strengthening Cancer Prevention Tactics With Mobile Screening Clinics
Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.
Formation of an Oncology Nurse Leader Council Promotes Frontline Nurse Engagement
Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, highlights how the Oncology Nurse Leader Council at her institution led to frontline nurse task-force engagement.
Seth Eisenberg Compares the Effectiveness of Plastic-Backed Pads Vs The Splashblocker in Reducing Toilet Aerosols
Seth Eisenberg, ASN, RN, OCN, BMTCN, discusses his research comparing plastic-backed pads and the Splashblocker.
Pattie Jakel Highlights the Challenges With Oral Therapies in Breast Cancer
Patricia Jakel, RN, MN, AOCN, underscores some of the challenges nurses face when promoting adherence to oral medications.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512